These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848 [TBL] [Abstract][Full Text] [Related]
6. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Shide K; Kameda T; Yamaji T; Sekine M; Inada N; Kamiunten A; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Shimoda H; Kitanaka A; Honda A; Sawaguchi A; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Shimoda K Leukemia; 2017 May; 31(5):1136-1144. PubMed ID: 27807369 [TBL] [Abstract][Full Text] [Related]
7. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Rivera JF; Baral AJ; Nadat F; Boyd G; Smyth R; Patel H; Burman EL; Alameer G; Boxall SA; Jackson BR; Baxter EJ; Laslo P; Green AR; Kent DG; Mullally A; Chen E Blood Adv; 2021 Apr; 5(7):1922-1932. PubMed ID: 33821991 [TBL] [Abstract][Full Text] [Related]
8. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927 [TBL] [Abstract][Full Text] [Related]
14. The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling. Olschok K; Altenburg B; de Toledo MAS; Maurer A; Abels A; Beier F; Gezer D; Isfort S; Paeschke K; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S Front Oncol; 2023; 13():1277453. PubMed ID: 37941547 [TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of calreticulin in myeloproliferative neoplasms. Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356 [TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
17. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806 [TBL] [Abstract][Full Text] [Related]
18. Mutant Calreticulin in the Myeloproliferative Neoplasms. Prins D; González Arias C; Klampfl T; Grinfeld J; Green AR Hemasphere; 2020 Feb; 4(1):e333. PubMed ID: 32382708 [TBL] [Abstract][Full Text] [Related]
19. Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus. Iborra FJ; Papadopoulos P Front Oncol; 2017; 7():103. PubMed ID: 28589084 [TBL] [Abstract][Full Text] [Related]
20. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. El-Khoury M; Cabagnols X; Mosca M; Vertenoeil G; Marzac C; Favale F; Bluteau O; Lorre F; Tisserand A; Rabadan Moraes G; Ugo V; Ianotto JC; Rey J; Solary E; Roy L; Rameau P; Debili N; Pasquier F; Casadevall N; Marty C; Constantinescu SN; Raslova H; Vainchenker W; Plo I Oncogene; 2020 Jul; 39(31):5323-5337. PubMed ID: 32572159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]